TEMPUS AI, INC. (TEM)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
$77.84+1.61%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
Research Workspace
Put TEM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 54% in its worst 12-month stretch.
View RiskTEM’s case rests on its revenue growth supporting higher 2026 guidance, despite weak recent financial performance. Q2 FY2026 revenue grew 22% year over year, and non-GAAP EPS beat consensus. TEM trades at 0.0× sales versus a 1.8× peer median. The desk says the price reflects less growth than its forecast expects. A next-quarter miss remains a risk, with our model putting its probability at 21%. The peer-multiple read says peer multiples imply a price about 13% below where it trades. Our standing thesis remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. TEM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering TEM (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for TEM in the last 4 months.
Continue this research
Compare TEM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TEM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put TEM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase 2026 revenue guidance to $1.595-$1.605 billion
Long-term expansion supports revenue growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $77.84
The last 12 months of price, then the range of analyst 12-month targets from today’s $77.84.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Increase 2026 revenue guidance to $1.595-$1.605 billion
Morgan Stanley's boost aligns with revenue growth objectives.
CEO stock sale raises concerns about leadership commitment.
Advances: Acquire Personalis to expand MRD capabilities
Personalis deal enhances MRD capabilities, supporting growth.
Advances: Acquire Personalis to expand MRD capabilities
Validation of strategy supports growth objectives.
Advances: Acquire Personalis to expand MRD capabilities
FDA clearance supports growth and product development.
High short interest indicates market skepticism.
Record short interest reflects negative sentiment.